Dostarlimab may cause immune-mediated adverse reactions.
Treatment of advanced endometrial cancer following prior treatment with a platinum-containing drug regimen.
Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor)
Dostarlimab may cause immune-mediated adverse reactions.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023